Bound a trend by its own arithmetic, express each factor twice in two geographies, and publish the losing transactions.
1. Bound an extrapolated trend by its own arithmetic
The repeatable method
- Take the trend everyone is extrapolating and ask what it implies if continued indefinitely.
- Where the implication is impossible — a share of a total exceeding 100% — you have a hard ceiling, which is stronger than any forecast.
- Then check whether the trend has ever reversed historically, using rolling multi-year windows rather than a single long chart.
- Look for current evidence that the reversal has started, and separate that evidence from the ceiling argument.
Here: "The US outperformance can't go on forever. If it did, US stocks would eventually make up 100% of the global stock market" — supported by rolling five-year windows showing alternating leadership, and by 2025 returns of 36.4% (Europe), 32.7% (Asia) and 25.9% (EM) against 18.1% for the S&P 500.
Watch for
- The ceiling being far away. "Cannot continue forever" says nothing about when, and this argument has been available and wrong for fifteen years.
2. Express every factor twice — once per accessible jurisdiction
The repeatable method
- Write down the factors you want exposure to (here: quality, size, multifactor, emerging markets) before choosing any funds.
- For each factor, find both a US-listed fund and a UCITS equivalent, because "if you live in the US, you can't buy non-US ETFs. And if you live outside the US, you can't buy US ETFs."
- Keep the two books at similar weights so the pair is comparable.
- Match on the factor and the index methodology, not on the sponsor's name.
Here: equal-weight, wide moat, small cap, mid/multi-factor quality, emerging markets and minimum volatility all exist in both books — RSP/MOAT/VB/XMHQ/USMV against GOAT.AS/IUSN.DE/MVOL.L and the untickered UCITS lines.
Watch for
- Imperfect twins. IQLT is developed-international while IEQU is Europe-only; the top ten overlap, the tail does not.
The repeatable method
- Chart each factor's US and non-US expression side by side over the same period.
- Read the dispersion: a wide gap means the return came from geography, not from the factor.
- Use that to decide where to add — the same idea at a much lower price is available on one side of the pair.
- Set the honest expectation that the gap is not predictive: "over time, I expect both portfolios to generate similar returns."
Here: small cap ~+44% (US) vs ~+15% (global); min vol ~+1% vs ~+16%; mid-cap quality ~+8% vs world multifactor ~+29%; wide moat ~+19% vs ~+11%. Same factors, opposite outcomes depending on the listing.
Watch for
- Currency. A euro-denominated twin and a dollar-denominated one are not measuring the same thing, and the issue does not adjust for it.
4. Publish the losing transactions, not just the aggregate return
The repeatable method
- Record every purchase with its date, price, quantity and current mark — not just the portfolio total.
- Show the negative lines with the same prominence as the positive ones.
- Revisit the reasoning given at the time of a losing purchase, so the process is reviewed rather than just the outcome.
- Report the portfolio CAGR alongside, so the individual lines can be seen in proportion.
Here: the February 2026 VB purchase at $277.32 is marked −7.60% six weeks later — the transaction the previous month's issue argued for on a "25-year-wide" small-cap valuation gap. The book: $9,528.99, 7.4% CAGR, seventeen purchases.
Watch for
- A short window flattering or damning a decision. Six weeks says nothing about a small-cap valuation thesis either way.
The repeatable method
- Define quality by three things you can measure from filings: return on equity (profitability), earnings variability (predictability) and debt-to-equity (safety).
- Apply the screen mechanically to a broad universe rather than case by case.
- Then look at what it actually bought — the resulting top ten is the real definition of the screen.
- Judge the screen by whether that portfolio is one you would want, not by the elegance of the rules.
Here: IQLT on ROE, earnings variability and D/E — producing ASML at 5.97%, then Shell, Novartis, Allianz, Roche, AstraZeneca, Nestlé, ABB, Zurich and Schneider. A European large-cap, healthcare-heavy book with an oil major in second place.
Watch for
- Trailing metrics buying cyclicals at peak earnings — the same caveat the archive raises against SPHQ's screen elsewhere.
6. Let the schedule, not the scoreboard, choose the position to top up
The repeatable method
- Decide in advance whether monthly additions go to the target-weight gap, the worst performer, or the strongest conviction — and write the rule down.
- If the rule is weight-based, it will systematically add to laggards, which is the intended behaviour, not a mistake.
- State whether any given purchase is the rule executing or a judgment overriding it.
- Review annually whether the laggards recovered — that is the test of the rule, not of any single purchase.
Here: $500 into USMV, the American book's smallest (5.3%) and weakest (+1%) line, with no argument offered this month — compare July 2026, where the same purchase is justified on an explicit high-vol/low-vol spread.
Watch for
- A rule quietly becoming a judgment. Adding to the laggard is defensible; adding to the laggard and then rationalising it afterwards is not the same thing.
Methods distilled from the archived Compounding Quality post for personal study. Not investment advice.